Cisatracurium Ups Some ARDS Outcomes Versus Vecuronium

This article originally appeared here.
Share this content:
Cisatracurium Ups Some ARDS Outcomes Versus Vecuronium
Cisatracurium Ups Some ARDS Outcomes Versus Vecuronium

WEDNESDAY, Dec. 20, 2017 (HealthDay News) -- Among patients with acute respiratory distress syndrome (ARDS), cisatracurium does not improve mortality versus vecuronium but is associated with improvements in other outcomes, according to a study published online in the American Journal of Respiratory and Critical Care Medicine.

Peter D. Sottile, M.D., from the University of Colorado School of Medicine in Aurora, and colleagues compared outcomes with cisatracurium and vecuronium in patients at risk for and with ARDS. The authors used propensity matching to balance patient- and hospital-specific factors in a cohort of 3,082 patients (1,901 per group).

The researchers found that there was no significant between-group difference in mortality (odds ratio, 0.932; P = 0.4) or hospital days (−0.66; P = 0.411). Fewer ventilator days (−1.01; P = 0.005) and intensive care unit days (−0.98; P = 0.28) were seen for patients treated with cisatracurium; however, they were equally likely to be discharged home (odds ratio, 1.19; P = 0.056).

"When compared to vecuronium, cisatracurium was not associated with a difference in mortality, but was associated with improvements in other clinically important outcomes," the authors write. "These data suggest that cisatracurium may be the preferred neuromuscular blocking agent for patients at risk for and with ARDS."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: First U.S. Case of Rat-Borne Andes Virus Diagnosed

CDC: First U.S. Case of Rat-Borne Andes Virus ...

New World hantavirus can present with symptoms similar to those of the flu

Variability in Geographic Availability of New Antibiotics

Variability in Geographic Availability of New Antibiotics

Greater geographic availability for antibiotics from and/or marketed by companies in U.S., Europe

CDC: Vaccination Rates More Than 95 Percent for Kindergartners

CDC: Vaccination Rates More Than 95 Percent for ...

Coverage could be even higher if schools followed up with under-vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »